ResearcherThe University of TokyoActive in the last 2 years
Satoru Abe
Matched on OpenAlex author ID A5105892346. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers
Papers 5
- Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy. Co-author DOI 10.1016/j.hpb.2025.12.021↗
- Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? Co-author DOI 10.1245/s10434-025-18511-2↗
- Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
- The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. Co-author DOI 10.1097/mpa.0000000000002291↗
- Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment. First author DOI 10.1016/j.asjsur.2023.03.162↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kiyoshi Hasegawa · 4 shared papers, 2024–2026 · strength 0.92
- Paper Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? DOI 10.1245/s10434-025-18511-2↗
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Paper The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. DOI 10.1097/mpa.0000000000002291↗
- Mitsuhiro Fujishiro · 3 shared papers, 2024–2026 · strength 0.63
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Paper The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. DOI 10.1097/mpa.0000000000002291↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Sho Kiritani · 2 shared papers, 2026 · strength 0.55
- Paper Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? DOI 10.1245/s10434-025-18511-2↗
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Yusuke Kazami · 2 shared papers, 2026 · strength 0.55
- Paper Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? DOI 10.1245/s10434-025-18511-2↗
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Takeshi Takamoto · 2 shared papers, 2026 · strength 0.55
- Paper Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? DOI 10.1245/s10434-025-18511-2↗
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Tatsunori Suzuki · 2 shared papers, 2025–2026 · strength 0.43
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Yousuke Nakai · 2 shared papers, 2024–2025 · strength 0.38
- Paper The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. DOI 10.1097/mpa.0000000000002291↗
- Paper Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overa… DOI 10.1245/s10434-025-17289-7↗
- Kazunaga Ishigaki · 1 shared paper, 2026 · strength 0.26
- Naminatsu Takahara · 1 shared paper, 2026 · strength 0.26
- Kazuhiko Koike · 1 shared paper, 2024 · strength 0.20
- Hideaki Ijichi · 1 shared paper, 2024 · strength 0.20
- Ryota Kogure · 1 shared paper, 2023 · strength 0.19
- Masahiko Komagome · 1 shared paper, 2023 · strength 0.19
- Yoshifumi Beck · 1 shared paper, 2023 · strength 0.19
- Riki Ninomiya · 1 shared paper, 2023 · strength 0.19
- Akifumi Kimura · 1 shared paper, 2023 · strength 0.19
- Yosuke Inoue · 1 shared paper, 2025 · strength 0.17
- Manabu Takamatsu · 1 shared paper, 2025 · strength 0.17
- Tsuyoshi Takeda · 1 shared paper, 2025 · strength 0.17
- Aya Maekawa · 1 shared paper, 2025 · strength 0.17
- Tsuyoshi Hamada · 1 shared paper, 2025 · strength 0.17
- Minoru Kitago · 1 shared paper, 2025 · strength 0.17
- Yohei Masugi · 1 shared paper, 2025 · strength 0.17
- Yu Takahashi · 1 shared paper, 2025 · strength 0.17
- Sho Uemura · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.